ELI LILLY & Co is 349.9x more valuable than Arcutis Biotherapeutics, Inc. by market capitalization ($1.067 T vs $3.05 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ARQT | LLY |
|---|---|---|
| Market cap | $3.05 B | $1.067 T |
| US-listed rank | #1814 | #11 |
| Revenue (latest FY) | $376.07M | $65.18B |
| Net income (latest FY) | -$16.14M | $20.64B |
| Net margin | -4.3% | 31.7% |
| P/E (trailing FY) | - | 51.7 |
| SEC filings | 798 | 989 |
ELI LILLY & Co is 349.9x more valuable than Arcutis Biotherapeutics, Inc. by market capitalization ($1.067 T vs $3.05 B).
In their latest fiscal years, Arcutis Biotherapeutics, Inc. reported $376.07M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Arcutis Biotherapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.